Data Insights

BT-5528 by Bicycle Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Non-Small Cell Lung Cancer

Data Insights

BT-5528 by Bicycle Therapeutics for Esophageal Cancer: Likelihood of Approval

BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Esophageal Cancer

Data Insights

BT-5528 by Bicycle Therapeutics for Pancreatic Cancer: Likelihood of Approval

BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Pancreatic Cancer

Data Insights

BT-5528 by Bicycle Therapeutics for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - BT-5528 in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Zelenectide pevedotin by Bicycle Therapeutics for Ureter Cancer: Likelihood of Approval

Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase III for Ureter Cancer. According to GlobalData,...

Data Insights

Zelenectide pevedotin by Bicycle Therapeutics for Urethral Cancer: Likelihood of Approval

Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase III for Urethral Cancer. According to GlobalData,...

Data Insights

Zelenectide pevedotin by Bicycle Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase III for Kidney Cancer (Renal Cell Cancer)....

Data Insights

Zelenectide pevedotin by Bicycle Therapeutics for Bladder Cancer: Likelihood of Approval

Zelenectide pevedotin is under clinical development by Bicycle Therapeutics and currently in Phase III for Bladder Cancer. According to GlobalData,...

Data Insights

BT-5528 by Bicycle Therapeutics for Pancreatic Cancer: Likelihood of Approval

BT-5528 is under clinical development by Bicycle Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Data Insights

BT-1718 by Bicycle Therapeutics for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Squamous Non-Small Cell Lung Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Endometrial Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Endometrial Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Solid Tumor: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Solid Tumor

Data Insights

BT-1718 by Bicycle Therapeutics for Bladder Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Bladder Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Gastric Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Gastric Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Colorectal Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Colorectal Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Ovarian Cancer: Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Ovarian Cancer

Data Insights

BT-1718 by Bicycle Therapeutics for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

BT-1718 is under clinical development by Bicycle Therapeutics and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - BT-1718 in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

BT-8009 by Bicycle Therapeutics for Ureter Cancer: Likelihood of Approval

BT-8009 is under clinical development by Bicycle Therapeutics and currently in Phase III for Ureter Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Ureter Cancer

Data Insights

BT-8009 by Bicycle Therapeutics for Urethral Cancer: Likelihood of Approval

BT-8009 is under clinical development by Bicycle Therapeutics and currently in Phase III for Urethral Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Urethral Cancer

Data Insights

BT-8009 by Bicycle Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

BT-8009 is under clinical development by Bicycle Therapeutics and currently in Phase III for Kidney Cancer (Renal Cell Cancer). According...

Likelihood of Approval and Phase Transition Success Rate Model - BT-8009 in Kidney Cancer (Renal Cell Cancer)